Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey

Italian Society of Surgical Oncology (SICO) Breast Oncoteam

Research output: Contribution to journalArticle

Abstract

The Italian Society of Surgical Oncology (SICO) Breast Oncoteam developed a survey to explore the state of the art of neoadjuvant treatment for breast cancer in Italy, specifically focusing on cases treated during the two-year period 2014-2015. A questionnaire was sent to Italian Breast Units with a minimum of 150 new breast cancer cases treated/year according to the Senonetwork directory and to the SICO Breast Oncoteam Breast Unit network. A total of 23/107 Breast Units submitted the survey, reporting a total amount of 20156 cases of breast carcinoma (17241 invasive, 2915 in situ) treated in the biennium, corresponding approximately to 20% of newly diagnosed breast cancers in Italy. In the United States, medical treatment before surgery for breast cancer is indicated in about 22.7% of newly diagnosed cases according to the National Cancer Database, while a German study reported approximately 20% of cases treated with neoadjuvant therapy. In our survey, a total of 1673/17241 cases (9.7%) were treated with neoadjuvant therapy, ranging from 2.9% to 23.6% according to different centres, showing heterogeneity in neoadjuvant treatment indications, even in multidisciplinary breast units. Better resources should be engaged to achieve a standardised quality indicator for neoadjuvant treatment, and this indicator could be included among the European Society of Breast Cancer Specialists (EUSOMA) quality indicators. In the near future, we plan to develop a second survey to better test improvements in the employment of neoadjuvant therapy after the expiry of the 2016 European Parliament deadline and after the 2017 St. Gallen Conference recommendations.

Original languageEnglish
Pages (from-to)1157-1163
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number8
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Neoadjuvant Therapy
Italy
Breast
Breast Neoplasms
Directories
Surveys and Questionnaires
Databases
Neoplasms

Keywords

  • Breast/pathology
  • Breast Neoplasms/diagnosis
  • Databases, Factual
  • Female
  • Follow-Up Studies
  • Humans
  • Italy/epidemiology
  • Morbidity/trends
  • Neoadjuvant Therapy/methods
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Societies, Medical
  • Surgical Oncology
  • Time Factors

Cite this

Neoadjuvant systemic treatment for breast cancer in Italy : The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey. / Italian Society of Surgical Oncology (SICO) Breast Oncoteam.

In: European Journal of Surgical Oncology, Vol. 44, No. 8, 08.2018, p. 1157-1163.

Research output: Contribution to journalArticle

@article{f7a95f926a814a7f8c81874100421d7d,
title = "Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey",
abstract = "The Italian Society of Surgical Oncology (SICO) Breast Oncoteam developed a survey to explore the state of the art of neoadjuvant treatment for breast cancer in Italy, specifically focusing on cases treated during the two-year period 2014-2015. A questionnaire was sent to Italian Breast Units with a minimum of 150 new breast cancer cases treated/year according to the Senonetwork directory and to the SICO Breast Oncoteam Breast Unit network. A total of 23/107 Breast Units submitted the survey, reporting a total amount of 20156 cases of breast carcinoma (17241 invasive, 2915 in situ) treated in the biennium, corresponding approximately to 20{\%} of newly diagnosed breast cancers in Italy. In the United States, medical treatment before surgery for breast cancer is indicated in about 22.7{\%} of newly diagnosed cases according to the National Cancer Database, while a German study reported approximately 20{\%} of cases treated with neoadjuvant therapy. In our survey, a total of 1673/17241 cases (9.7{\%}) were treated with neoadjuvant therapy, ranging from 2.9{\%} to 23.6{\%} according to different centres, showing heterogeneity in neoadjuvant treatment indications, even in multidisciplinary breast units. Better resources should be engaged to achieve a standardised quality indicator for neoadjuvant treatment, and this indicator could be included among the European Society of Breast Cancer Specialists (EUSOMA) quality indicators. In the near future, we plan to develop a second survey to better test improvements in the employment of neoadjuvant therapy after the expiry of the 2016 European Parliament deadline and after the 2017 St. Gallen Conference recommendations.",
keywords = "Breast/pathology, Breast Neoplasms/diagnosis, Databases, Factual, Female, Follow-Up Studies, Humans, Italy/epidemiology, Morbidity/trends, Neoadjuvant Therapy/methods, Neoplasm Staging, Prognosis, Retrospective Studies, Societies, Medical, Surgical Oncology, Time Factors",
author = "{Italian Society of Surgical Oncology (SICO) Breast Oncoteam} and E Vicini and A Invento and M Cuoghi and A Bafile and C Battaglia and N Biglia and M Busani and R Bussone and E Cianchetti and F Caruso and Cucchi, {M C} and M Dessena and {Di Filippo}, F and N Fabi and S Folli and D Friedman and G Macellari and P Mainente and R Murgo and A Neri and Pollini, {G P} and D Palli and F Ricci and G Scalco and M Taffurelli and M Trunfio and V Galimberti",
note = "Copyright {\circledC} 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.",
year = "2018",
month = "8",
doi = "10.1016/j.ejso.2018.03.018",
language = "English",
volume = "44",
pages = "1157--1163",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Neoadjuvant systemic treatment for breast cancer in Italy

T2 - The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey

AU - Italian Society of Surgical Oncology (SICO) Breast Oncoteam

AU - Vicini, E

AU - Invento, A

AU - Cuoghi, M

AU - Bafile, A

AU - Battaglia, C

AU - Biglia, N

AU - Busani, M

AU - Bussone, R

AU - Cianchetti, E

AU - Caruso, F

AU - Cucchi, M C

AU - Dessena, M

AU - Di Filippo, F

AU - Fabi, N

AU - Folli, S

AU - Friedman, D

AU - Macellari, G

AU - Mainente, P

AU - Murgo, R

AU - Neri, A

AU - Pollini, G P

AU - Palli, D

AU - Ricci, F

AU - Scalco, G

AU - Taffurelli, M

AU - Trunfio, M

AU - Galimberti, V

N1 - Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

PY - 2018/8

Y1 - 2018/8

N2 - The Italian Society of Surgical Oncology (SICO) Breast Oncoteam developed a survey to explore the state of the art of neoadjuvant treatment for breast cancer in Italy, specifically focusing on cases treated during the two-year period 2014-2015. A questionnaire was sent to Italian Breast Units with a minimum of 150 new breast cancer cases treated/year according to the Senonetwork directory and to the SICO Breast Oncoteam Breast Unit network. A total of 23/107 Breast Units submitted the survey, reporting a total amount of 20156 cases of breast carcinoma (17241 invasive, 2915 in situ) treated in the biennium, corresponding approximately to 20% of newly diagnosed breast cancers in Italy. In the United States, medical treatment before surgery for breast cancer is indicated in about 22.7% of newly diagnosed cases according to the National Cancer Database, while a German study reported approximately 20% of cases treated with neoadjuvant therapy. In our survey, a total of 1673/17241 cases (9.7%) were treated with neoadjuvant therapy, ranging from 2.9% to 23.6% according to different centres, showing heterogeneity in neoadjuvant treatment indications, even in multidisciplinary breast units. Better resources should be engaged to achieve a standardised quality indicator for neoadjuvant treatment, and this indicator could be included among the European Society of Breast Cancer Specialists (EUSOMA) quality indicators. In the near future, we plan to develop a second survey to better test improvements in the employment of neoadjuvant therapy after the expiry of the 2016 European Parliament deadline and after the 2017 St. Gallen Conference recommendations.

AB - The Italian Society of Surgical Oncology (SICO) Breast Oncoteam developed a survey to explore the state of the art of neoadjuvant treatment for breast cancer in Italy, specifically focusing on cases treated during the two-year period 2014-2015. A questionnaire was sent to Italian Breast Units with a minimum of 150 new breast cancer cases treated/year according to the Senonetwork directory and to the SICO Breast Oncoteam Breast Unit network. A total of 23/107 Breast Units submitted the survey, reporting a total amount of 20156 cases of breast carcinoma (17241 invasive, 2915 in situ) treated in the biennium, corresponding approximately to 20% of newly diagnosed breast cancers in Italy. In the United States, medical treatment before surgery for breast cancer is indicated in about 22.7% of newly diagnosed cases according to the National Cancer Database, while a German study reported approximately 20% of cases treated with neoadjuvant therapy. In our survey, a total of 1673/17241 cases (9.7%) were treated with neoadjuvant therapy, ranging from 2.9% to 23.6% according to different centres, showing heterogeneity in neoadjuvant treatment indications, even in multidisciplinary breast units. Better resources should be engaged to achieve a standardised quality indicator for neoadjuvant treatment, and this indicator could be included among the European Society of Breast Cancer Specialists (EUSOMA) quality indicators. In the near future, we plan to develop a second survey to better test improvements in the employment of neoadjuvant therapy after the expiry of the 2016 European Parliament deadline and after the 2017 St. Gallen Conference recommendations.

KW - Breast/pathology

KW - Breast Neoplasms/diagnosis

KW - Databases, Factual

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Italy/epidemiology

KW - Morbidity/trends

KW - Neoadjuvant Therapy/methods

KW - Neoplasm Staging

KW - Prognosis

KW - Retrospective Studies

KW - Societies, Medical

KW - Surgical Oncology

KW - Time Factors

U2 - 10.1016/j.ejso.2018.03.018

DO - 10.1016/j.ejso.2018.03.018

M3 - Article

C2 - 29653781

VL - 44

SP - 1157

EP - 1163

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 8

ER -